Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha

Cancer Science

Volumn 96, Issue 11, 2005, Pages 774-783

  de Lucio, Bautista ^a   Manuel, Victor ^a   Barrera Rodríguez, Raul ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CAMPTOTHECIN; CYTOPLASM PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; TENIPOSIDE;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CELL LINE; CYTOPLASM; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOLECULAR WEIGHT; NORTHERN BLOTTING; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; TRANSCRIPTION REGULATION; TUMOR CELL; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CYTOPLASM; DNA MUTATIONAL ANALYSIS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 29644440842     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00111.x     Document Type: Article

References (37)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65: 635-92.
2. Champoux JJ. DNA topoisomerases: Structure, function and mechanism. Annu Rev Biochem 2001; 70: 369-413.
3. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 350-75.
4. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400: 139-54.
5. Bugg BY, Danks MK, Beck WT, Suttle DP. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 1991; 88: 7654-8.
6. Danks MK, Warmoth MR, Friche E et al. Single-strand conformational polymorphism analysis of the M(r) 170 000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res 1993; 53: 1373-9.
7. Hinds M, Deisseroth K, Mayes J et al. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 1991; 51: 4729-31.
8. Lee MS, Wang JC, Beran M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 1992; 223: 837-43.
9. Campain JA, Gottesman MM, Pasta I. A novel mutant topoisomerase II alpha present in VP-16 resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry 1994; 33: 11327-32.
10. Takano H, Ise T, Nomoto M et al. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells. Anticancer Drug Des 1999; 14: 87-92.
11. Patel S, Fisher LM. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line. Br J Cancer 1993; 67: 456-63.
12. Kubo A, Yoshikawa A, Hirashima T et al. Point mutations of the topoisomerase II alpha gene in patients with small cell lung cancer treated with etoposide. Cancer Res 1996; 56: 1232-6.
13. Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 1990; 26: 313-7.
14. Wessel I, Jensen PB, Falck J, Mirski SE, Cole SP, Sehested M. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase II alpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res 1997; 57: 4451-4.
15. Mirski SE, Evans CD, Almquist KC, Slovak ML, Cole SP. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 1993; 53: 4866-73.
16. Feldhoff PW, Mirski SE, Cole SP, Sullivan DM. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994; 54: 756-62.
17. Mirski SE, Cole SP. Cytoplasmic localization of a mutant M(r) 160 000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 1995; 55: 2129-34.
18. Yu Q, Mirski SE, Sparks KE, Cole SP. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing. Biochemistry 1997; 36: 5868-77.
19. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 1995; 55: 1707-16.
20. Harker WG, Slade DL, Parr RL, Holguin MH. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res 1995; 55: 4962-71.
21. Jain N, Lam YM, Pym J, Campling BG. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 1996; 77: 1797-808.
22. Mirski SE, Sparks KE, Yu Q et al. A truncated cytoplasmic topoisomerase II alpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34. Int J Cancer 2000; 85: 534-9.
23. Mo YY, Beck WT. Heterogeneous expression of DNA topoisomerase II α isoforms in tumor cell lines. Oncol Res 1997; 9: 193-204.
24. Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res 2001; 92: 1133-7.
25. Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Hypophosphorylation of topoisomerase II alpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation. Jpn J Cancer Res 2001; 92: 799-805.
26. Mirski SEL, Gerlach JH, Cole SPC. Sequence determinants of nuclear localization in the α and β isoforms of human topoisomerase II. Exp Cell Res 1999; 251: 329-39.
27. Cole SP. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 1986; 17: 259-63.
28. de Jong S, Zijlstra JG, de Vries EG, Mulder NH. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 1990; 50: 304-9.
29. Brost P, Elferink RO. Mammalian ABC transporters in health and disease. Ann Rev Biochem 2002; 71: 537-92.
30. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996; 32A: 958-66.
31. Adachi N, Miyaike M, Kato S, Kanamaru R, Koyama H, Kikuchi A. Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain. Nucleic Acids Res 1997; 25: 3135-42.
32. Ernst IA, Soltermann A, Sigrist JA, Widmer L, Gasser SM, Stahel A. Ectopic expression of human topoisomerase IIα fragments and etoposide resistance in mammalian cells. Int J Cancer 2000; 88: 99-107.
33. Tavormina PA, Come MG, Hudson JR, Mo YY, Beck WT, Gorbsky GJ. Rapid exchange of mammalian topoisomerase II alpha at kinetochores and chromosome arms in mitosis. J Cell Biol 2002; 158: 23-9.
34. Grue P, Grasser A, Sehested M et al. Essential mitotic functions of DNA topoisomerase II alpha are not adopted by topoisomerase II beta in human H69 cells. J Biol Chem 1998; 273: 33660-6.
35. Kusumoto H, Rodgers QE, Boege F, Raimondi SC, Beck WT. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res 1966; 56: 2573-83.
36. Grandgirard N, Ly-Sunnaram B, Ferrant D et al. Impact of topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemia. Leukemia Res 2004; 28: 479-86.
37. Goswami PC, Sheren J, Albee LD et al. Cell cycle-coupled variation in topoisomerase II alpha mRNA is regulated by the 3′-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation. J Biol Chem 2000; 275: 38384-92.